Tamoxifen (TAM; a selective estrogen receptor modulator), which has so far been used mainly as an adjuvant therapeutic in breast cancer, in recent preclinical studies has shown the potential to alleviate ovarian side effects of cancer treatment [8–10]. This evidence concerns the gene ESR1 and breast carcinoma.